--(BUSINESS WIRE)-- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced the relaunch of TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg ...
Purpose: The stability of a triamcinolone acetonide mouthwash and its efficacy in treating oral lichen planus are described. Results: The mouthwash had a satisfactory shelf life and was well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback